Posted 2 weeks ago

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

ClinicalTrials.gov ID NCT05211895

Protocol number PACIFIC-8 D9075C00001

Sponsor Astra Zeneca